H&H INTL HLDG

1112
26.1203.57% ( +0.900 )
Delay Closed: Nov 16, 16:08:11

Overview

H&H INTL HLDG (1112)

Health and Happiness (H&H) International Holdings Limited, an investment holding company, manufactures and sells pediatric nutrition, baby care, adult nutrition...

Open
25.220
High
26.500
Low
24.840
Prev. Close
25.220
Volume
2.40M
Turnover
62.25M
Avg Price
25.911
Bid/Ask Ratio
-28.57%
Amplitude
6.58%
52wk High
26.500
Volume Ratio
1.02
Turnover Ratio
0.37%
52wk Low
9.280
HK Mkt Cap
16.86B
Market CapHKD
16.86B
P/ETTM
19.91
P/EDynamic
11.99
P/EStatic
--
EPSTTM
1.31
EPSDynamic
2.18
EPSStatic
--
BVPS
11.62
P/B
2.25
HK Shares
645.56M
Dividend YieldTTM
3.75%
DividendTTM
0.98
Shares
645.56M
Min lot size
500
Currency
HKD

H&H INTL HLDG Analyst Rating

View more

Forecast & Rating

Nov 2, 2026
Price forecast
HK$29.7113.76%
Forecast & RatingStrong buy
9analysts
  • Strong buy77.78%
  • Buy22.22%
  • Hold0.00%
  • Sell0.00%
  • Strong sell0.00%

Daily Events

  1. Jul, 3

    Health and Happiness (H&H) International Holdings (1112.HK) staged a low-open rally, closing up 6.59% at HK$11.32, fueled by strong Q4 earnings and bullish institutional sentiment. The stock opened at HK$10.68 and rebounded sharply, hitting an intraday high of HK$11.47 with total turnover of approximately HK$21.15 million. Q4 operating revenue rose 20.55% YoY to HK$4.078 billion, net profit surged 136.38% YoY to HK$69.57 million, and EPS jumped 136.32% YoY to HK$0.1084, underscoring a significant profitability turnaround. CLSA and China Merchants Securities recently reiterated Buy ratings. However, the stock remains down 13.85% year-to-date and 32.62% off its 52-week high of HK$16.80, now trading above its 20-day MA (HK$10.80) but below the 60-day MA (HK$12.36), leaving the divergence between short-term momentum and medium-term trend as a cautionary note.

  2. Jul, 2

    健合国际今日低开高走,开盘短暂下探 10.26 港元的日内低点后震荡上行,下午盘一度触及 10.70 港元高位,最终收报 10.60 港元,较前收 10.18 港元涨 4.1%。推动股价的主要利好来自一季度财报改善,营收 40.78 亿港元同比增长 20.55%,净利润 6957 万港元同比猛增 136.38%,EPS 达 0.1084 港元,较上年同期增逾 1.3 倍。此外,CLSA 与招商证券近期重申买入评级,且公司于世界微生物日推广婴幼儿益生菌新品,强化了市场情绪。不过,当前股价距 52 周高点 16.8 港元仍下滑 36.9%,且低于 20 日均线 (10.805 港元) 和 60 日均线 (12.377 港元),估值修复尚需更多业绩确认。

News